All In Biotech

Drug Trial Radar · NCT01700192

Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)

Last checked: Nov 19, 2026Latest source record: Sep 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,482 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,482

Actual

Start

Jan 2013

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
ALK-Abelló A/SIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults. The primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).

Conditions

  • Rhinitis, Allergic, Perennial
  • Rhinitis, Allergic, Nonseasonal

Interventions

  • MK-8237 tabletsBiological

    MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.

  • Placebo tabletsBiological

    Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.

  • Rescue Medication: Self-Injectable EpinephrineDrug

    Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.

  • Rescue Medication: Loratadine tabletsDrug

    Loratadine tablet 10 mg administered orally as needed for rescue medication.

  • Rescue Medication: Olopatadine ophthalmic dropsDrug

    Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.

  • Rescue Medication: Mometasone furoate nasal sprayDrug

    Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of TreatmentTime frame: Last 8 weeks of treatment (Weeks 44 to 52)
  2. Number of Participants Who Experience At Least One Adverse Event (AE)Time frame: Up to 54 weeks
  3. Number of Participants Who Discontinue Study Drug Due to an AETime frame: Up to 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.